Why the study?
FFAR3 is associated with insulin sensitivity and elevated in early Alzheimer disease pathology, suggesting it may play a key role linking obesity, insulin resistance, and dementia onset and progression.
Does Ffar3 gene ablation prevent cognitive deficiencies and brain hypermetabolism in Tg2576 mice exposed to a high-fat diet?
Does Ffar3 gene ablation prevent cognitive deficiencies and brain hypermetabolism in Tg2576 mice exposed to a high-fat diet?
FFAR3 ablation prevents cognitive decline and brain hypermetabolism in an Alzheimer's mouse model, even under diet-induced obesity, suggesting FFAR3 as a potential therapeutic target for AD.
Supports targeting obesity/insulin resistance for AD prevention; leaves open causal mechanisms in aging populations.
Obesity and aging are becoming increasingly prevalent across the globe. It has been established that aging is the major risk factor for Alzheimer’s disease (AD), and it is becoming increasingly evident that obesity and the associated insulin resistance are also notably relevant risk factors. The biological plausibility of the link between high adiposity, insulin resistance, and dementia is central for understanding AD etiology, and to form bases for prevention efforts to decrease the disease burden. Several studies have demonstrated a strong association between short chain fatty acid receptor FFAR3 and insulin sensitivity. Interestingly, it has been recently established that FFAR3 mRNA levels are increased in early stages of the AD pathology, indicating that FFAR3 could play a key role in AD onset and progression. Indeed, in the present study we demonstrate that the ablation of the Ffar3 gene in Tg2576 mice prevents the development of cognitive deficiencies in advanced stages of the disease. Notably, this cognitive improvement is also maintained upon a severe metabolic challenge such as the exposure to high-fat diet (HFD) feeding. Moreover, FFAR3 deletion restores the brain hypermetabolism displayed by Tg2576 mice. Collectively, these data postulate FFAR3 as a potential novel target for AD.
No takes yet. Share an insight, caveat, or question.
Solas et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: